John Leaman
2020 - IMPEL PHARMACEUTICALS
In 2020, John Leaman earned a total compensation of $538.7K as Chief Financial & Business Officer at IMPEL PHARMACEUTICALS.
Compensation breakdown
| Non-Equity Incentive Plan | $123,463 |
|---|---|
| Salary | $415,231 |
| Total | $538,694 |
Leaman received $415.2K in salary, accounting for 77% of the total pay in 2020.
Leaman also received $123.5K in non-equity incentive plan.
Rankings
In 2020, John Leaman's compensation ranked 10,825th out of 13,090 executives tracked by ExecPay. In other words, Leaman earned more than 17.3% of executives.
| Classification | Ranking | Percentile |
|---|---|---|
All | 10,825 out of 13,090 | 17th |
Division Manufacturing | 4,623 out of 5,621 | 18th |
Major group Chemicals And Allied Products | 1,918 out of 2,254 | 15th |
Industry group Drugs | 1,682 out of 1,954 | 14th |
Industry Pharmaceutical Preparations | 1,241 out of 1,459 | 15th |
Source: SEC filing on April 26, 2022.
Leaman's colleagues
We found one more compensation record of an executive who worked with John Leaman at IMPEL PHARMACEUTICALS in 2020.
2020
Adrian Adams
IMPEL PHARMACEUTICALS